SAB Corporate Presentation August 31, 2026 BT1D Congress 2026 - Profiling the binding specificities of SAB-142, a fully human anti-thymocyte globulin, against T-cell surface proteins October 10, 2026 BT1D Congress 2026 - Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with T1D > 100 days post diagnosis October 10, 2026 BT1D Congress 2026 - SAB-142, a fully human anti-thymocyte globulin, can be safely redosed, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers October 10, 2026 BT1D Congress 2026 - Save All Beta Cells: Sustained Autoimmune Balance with SAB-142 Induction and Maintenance Dosing October 10, 2026 BT1D Congress 2026 - Tracking multiplicity: clinical pharmacokinetic assay for SAB-142, a multi-target therapeutic for T1D October 10, 2026 EASD 2026 - Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with type 1 diabetes > 100 days post diagnosis September 30, 2026 EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, can be safely readministered, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers September 30, 2026 EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, demonstrated anticipated PD profiles and early efficacy signals in T1D patients with residual C-peptide September 30, 2026 EASD 2026 - SAB-142: Setting a New Standard for Beta-Cell Preservation September 30, 2026 FOCiS 2026 - Positive Clinical Translation of a Juvenile NHP Study for Evaluating SAB-142, a Multi-Specific T-Cell Targeting T1D Therapy, in Humans June 10, 2026
BT1D Congress 2026 - Profiling the binding specificities of SAB-142, a fully human anti-thymocyte globulin, against T-cell surface proteins October 10, 2026
BT1D Congress 2026 - Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with T1D > 100 days post diagnosis October 10, 2026
BT1D Congress 2026 - SAB-142, a fully human anti-thymocyte globulin, can be safely redosed, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers October 10, 2026
BT1D Congress 2026 - Save All Beta Cells: Sustained Autoimmune Balance with SAB-142 Induction and Maintenance Dosing October 10, 2026
BT1D Congress 2026 - Tracking multiplicity: clinical pharmacokinetic assay for SAB-142, a multi-target therapeutic for T1D October 10, 2026
EASD 2026 - Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with type 1 diabetes > 100 days post diagnosis September 30, 2026
EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, can be safely readministered, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers September 30, 2026
EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, demonstrated anticipated PD profiles and early efficacy signals in T1D patients with residual C-peptide September 30, 2026
FOCiS 2026 - Positive Clinical Translation of a Juvenile NHP Study for Evaluating SAB-142, a Multi-Specific T-Cell Targeting T1D Therapy, in Humans June 10, 2026
